Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STABLE Wt Loss: Semaglutide on Appetite and Eating Behavior in Obesity
NCT05548647Phase 4Completed
- Sponsor
- University of Pennsylvania
- Start
- Jul 2022
- Primary completion
- May 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of semaglutide in obesity, sponsored by University of Pennsylvania. Started Jul 2022; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05548647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05548647.